Macrolides as antiinflammatory agents in CAP

European Respiratory Monograph

Volumn 63, Issue , 2014, Pages 243-255

  Salih, Waleed ^a   Short, Philip M ^a   Schembri, Stuart ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(8,9) 8,9 DIHYDRO 6,9 EPOXY 8,9 ANHYDROPSEUDOERYTHROMYCIN; AMINOGLYCOSIDE; AMOXICILLIN; AZITHROMYCIN; BENZODIAZEPINE; CLARITHROMYCIN; CYTOCHROME P450 3A; EM900; ERYTHROMYCIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MACROLIDE; NEUROLEPTIC AGENT; PLACEBO; PNEUMOLYSIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; SIMVASTATIN; TELITHROMYCIN; TETRACYCLINE; THEOPHYLLINE; TRIAZOLAM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WARFARIN;

ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; CARDIOTOXICITY; CLINICAL PRACTICE; COMMUNITY ACQUIRED PNEUMONIA; CYTOKINE PRODUCTION; DRUG INDUCED DISEASE; DRUG TOLERABILITY; HEARING IMPAIRMENT; HUMAN; IMMUNOMODULATION; MULTICENTER STUDY (TOPIC); NEUTROPHIL CHEMOTAXIS; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84905757420     PISSN: 1025448X     EISSN: 20756674     Source Type: Book Series    
DOI: 10.1183/1025448x.10004713     Document Type: Review

References (95)

1. Woodward RB, Logusch E, Nambiar KP, et al. Asymmetric total synthesis of erythromcin. 1. Synthesis of an erythronolide a seco acid derivativeviaasymmetric induction. J Am Chem Soc 1981; 103: 3210-3213.
2. Waddington WS, Maple FM, Kirby WM. Treatment of bacterial pneumonia with erythromycin. AMA Arch Intern Med 1954; 93: 556-560.
3. Gaynor M, Mankin AS. Macrolide antibiotics: binding site, mechanism of action, resistance. Curr Top Med Chem 2003; 3: 949-961.
4. Leclercq R, Courvalin P. Resistance to macrolides and related antibiotics inStreptococcus pneumoniae. Antimicrob Agents Chemother 2002; 46: 2727-2734.
5. Zuckerman JM. Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin North Am 2004; 18: 621-649.
6. Ruiz M, Ewig S, Marcos MA, et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999; 160: 397-405.
7. Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med 1999; 159: 970-980.
8. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: Suppl. 2, S27-S72.
9. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64: Suppl. 3, iii1-iii55.
10. Stahl JE, Barza M, DesJardin J, et al. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999; 159: 2576-2580.
11. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to ab-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36: 389-395.
12. Brown RB, Iannini P, Gross P, et al. Impact of initial antibiotic choice on clinical outcomes in communityacquired pneumonia: analysis of a hospital claims-made database. Chest 2003; 123: 1503-1511.
13. Sligl WI, Asadi L, Eurich DT, et al. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med2013 [In press DOI: 10. 1097/CCM. 0b013e3182a66b9b].
14. Restrepo MI, Mortensen EM, Waterer GW, et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J2009; 33: 153-159.
15. Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010; 36: 612-620.
16. Rodríguez A, Mendia A, Sirvent JM, et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007; 35: 1493-1498.
17. Lodise TP, Kwa A, Cosler L, et al. Comparison of b-lactam and macrolide combination therapyversus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother 2007; 51: 3977-3982.
18. Giamarellos-Bourboulis EJ, Pechère JC, Routsi C, et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 2008; 46: 1157-1164.
19. Asadi L, Sligl WI, Eurich DT, et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2012; 55: 371-380.
20. Eliakim-Raz N, Robenshtok E, Shefet D, et al. Empiric antibiotic coverage of atypical pathogens for communityacquired pneumonia in hospitalized adults. Cochrane Database Syst Rev 2012; 9: CD004418. pub4.
21. Amsden GW. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?J Antimicrob Chemother 2005; 55: 10-21.
22. Kudoh S. Erythromycin treatment in diffuse panbronchiolitis. Curr Opin Pulm Med 1998; 4: 116-121.
23. Kudoh S, Azuma A, Yamamoto M, et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998; 157: 1829-1832.
24. Yamamoto M, Kondo A, Tamura M, et al. [Long-term therapeutic effects of erythromycin and newquinolone antibacterial agents on diffuse panbronchiolitis]. Nihon Kyobu Shikkan Gakkai Zasshi 1990; 28: 1305-1313.
25. Aoki Y, Kao PN. Erythromycin inhibits transcriptional activation of NF-kB, but not NFAT, through calcineurinindependent signaling in T cells. Antimicrob Agents Chemother 1999; 43: 2678-2684.
26. Cigana C, Assael BM, Melotti P. Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother 2007; 51: 975-981.
27. Tsai WC, Rodriguez ML, Young KS, et al. Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am J Respir Crit Care Med 2004; 170: 1331-1339.
28. Sakito O, Kadota J, Kohno S, et al. Interleukin 1b, tumor necrosis factor a, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 1996; 63: 42-48.
29. Oishi K, Sonoda F, Kobayashi S, et al. Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun 1994; 62: 4145-4152.
30. Kohyama T, Takizawa H, Kawasaki S, et al. Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. Antimicrob Agents Chemother 1999; 43: 907-911.
31. Culić O, Eraković V, Cepelak I, et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 2002; 450: 277-289.
32. Nakamura H, Fujishima S, Inoue T, et al. Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur Respir J1999; 13: 1371-1379.
33. Savill JS, Wyllie AH, Henson JE, et al. Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest 1989; 83: 865-875.
34. Kanai K, Asano K, Hisamitsu T, et al. Suppression of matrix metalloproteinase production from nasal fibroblasts by macrolide antibioticsin vitro. Eur Respir J2004; 23: 671-678.
35. Inamura K, Ohta N, Fukase S, et al. The effects of erythromycin on human peripheral neutrophil apoptosis. Rhinology 2000; 38: 124-129.
36. Aoshiba K, Nagai A, Konno K. Erythromycin shortens neutrophil survival by accelerating apoptosis. Antimicrob Agents Chemother 1995; 39: 872-877.
37. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010; 23: 590-615.
38. Kusano S, Kadota J, Kohno S, et al. Effect of roxithromycin on peripheral neutrophil adhesion molecules in patients with chronic lower respiratory tract disease. Respiration 1995; 62: 217-222.
39. Finsnes F, Skjønsberg OH, Tønnessen T, et al. Endothelin production and effects of endothelin antagonism during experimental airway inflammation. Am J Respir Crit Care Med 1997; 155: 1404-1412.
40. Takizawa H, Desaki M, Ohtoshi T, et al. Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchial epithelial cells. Eur Respir J1998; 12: 57-63.
41. Perry DK, Hand WL, Edmondson DE, et al. Role of phospholipase D-derived diradylglycerol in the activation of the human neutrophil respiratory burst oxidase. Inhibition by phosphatidic acid phosphohydrolase inhibitors. J Immunol 1992; 149: 2749-2758.
42. Sibille Y, Reynolds HY. Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis 1990; 141: 471-501.
43. Lin CC, Liaw SF, Wu KM, et al. Effect of erythromycin on bronchial hyperreactivity and inflammation in ovalbumin-sensitized brown Norway rats. Respir Physiol Neurobiol 2008; 161: 267-272.
44. Weitzman S, Berger S. Clinical trial design in studies of corticosteroids for bacterial infections. Ann Intern Med 1974; 81: 36-42.
45. Meijvis SC, van de Garde EM, Rijkers GT, et al. Treatment with anti-inflammatory drugs in community-acquired pneumonia. J Intern Med 2012; 272: 25-35.
46. Morikawa K, Zhang J, Nonaka M, et al. Modulatory effect of macrolide antibiotics on the Th1-and Th2-type cytokine production. Int J Antimicrob Agents 2002; 19: 53-59.
47. Van Langevelde P, van Dissel JT, Ravensbergen E, et al. Antibiotic-induced release of lipoteichoic acid and peptidoglycan fromStaphylococcus aureus: quantitative measurements and biological reactivities. Antimicrob Agents Chemother 1998; 42: 3073-3078.
48. Lagrou K, Peetermans WE, Jorissen M, et al. Subinhibitory concentrations of erythromycin reduce pneumococcal adherence to respiratory epithelial cellsin vitro. J Antimicrob Chemother 2000; 46: 717-723.
49. Kazachkov MY, Hu PC, Carson JL, et al. Release of cytokines by human nasal epithelial cells and peripheral blood mononuclear cells infected withMycoplasma pneumoniae. Exp Biol Med (Maywood)2002; 227: 330-335.
50. Koch CC, Esteban DJ, Chin AC, et al. Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin: effects ofStreptococcus pneumoniae. J Antimicrob Chemother 2000; 46: 19-26.
51. Chmura K, Bai X, Nakamura M, et al. Induction of IL-8 byMycoplasma pneumoniaemembrane in BEAS-2B cells. Am J Physiol Lung Cell Mol Physiol 2008; 295: L220-L30.
52. Uriarte SM, Molestina RE, Miller RD, et al. Effect of macrolide antibiotics on human endothelial cells activated by Chlamydia pneumoniaeinfection and tumor necrosis factor-a. J Infect Dis 2002; 185: 1631-1636.
53. Abdelaziz MM, Devalia JL, Khair OA, et al. The effect of conditioned medium from cultured human bronchial epithelial cells on eosinophil and neutrophil chemotaxis and adherencein vitro. Am J Respir Cell Mol Biol 1995; 13: 728-737.
54. Rios AM, Fonseca-Aten M, Mejías A, et al. Microbiologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimentalMycoplasma pneumoniaepneumonia. Antimicrob Agents Chemother 2005; 49: 3970-3973.
55. Rios AM, Mejias A, Chavez-Bueno S, et al. Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model ofMycoplasma pneumoniaelower respiratory infection. Antimicrob Agents Chemother 2004; 48: 2897-2904.
56. Hardy RD, Rios AM, Chavez-Bueno S, et al. Antimicrobial and immunologic activities of clarithromycin in a murine model ofMycoplasma pneumoniae-induced pneumonia. Antimicrob Agents Chemother 2003; 47: 1614-1620.
57. Duong M, Simard M, Bergeron Y, et al. Kinetic study of the inflammatory response inStreptococcus pneumoniae experimental pneumonia treated with the ketolide HMR 3004. Antimicrob Agents Chemother 2001; 45: 252-262.
58. Tagliabue C, Salvatore CM, Techasaensiri C, et al. The impact of steroids given with macrolide therapy on experimentalMycoplasma pneumoniaerespiratory infection. J Infect Dis 2008; 198: 1180-1188.
59. Nakamura S, Yanagihara K, Araki N, et al. Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistantHaemophilus influenzaein mice. Antimicrob Agents Chemother 2010; 54: 757-762.
60. Yasuda Y, Kasahara K, Mizuno F, et al. Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniaein a murine pneumonia model. Antimicrob Agents Chemother 2007; 51: 1741-1752.
61. Demartini G, Esposti D, Marthyn P, et al. Effect of multiple doses of clarithromycin and amoxicillin on IL-6, IFNc and IL-10 plasma levels in patients with community acquired pneumonia. J Chemother 2004; 16: 82-85.
62. Spyridaki A, Raftogiannis M, Antonopoulou A, et al. Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis cause by Gram-negative bacteria: results from a randomized clinical study. Antimicrob Agents Chemother 2012; 56: 3819-3825.
63. Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA2013; 110: 3507-3512.
64. Anderson R, Steel HC, Cockeran R, et al. Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin byStreptococcus pneumoniae in vitro. J Antimicrob Chemother 2007; 60: 1155-1158.
65. Steel HC, Theron AJ, Cockeran R, et al. Pathogen-and host-directed anti-inflammatory activities of macrolide antibiotics. Mediators Inflamm 2012; 2012: 584262.
66. Kimmitt PT, Harwood CR, Barer MR. Induction of type 2 Shiga toxin synthesis inEscherichia coliO157 by 4-quinolones. Lancet 1999; 353: 1588-1589.
67. Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coliO157: H7 infections. N Engl J Med 2000; 342: 1930-1936.
68. Stevens DL, Ma Y, Salmi DB, et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistantStaphylococcus aureus. J Infect Dis 2007; 195: 202-211.
69. Dumitrescu O, Badiou C, Bes M, et al. Effect of antibiotics, alone and in combination, on Panton-Valentine leukocidin production by a Staphylococcus aureusreference strain. Clin Microbiol Infect 2008; 14: 384-388.
70. Serna At., Boedeker EC. Pathogenesis and treatment of Shiga toxin-producingEscherichia coliinfections. Curr Opin Gastroenterol 2008; 24: 38-47.
71. McGannon CM, Fuller CA, Weiss AA. Different classes of antibiotics differentially influence shiga toxin production. Antimicrob Agents Chemother 2010; 54: 3790-3798.
72. Karchmer AW. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US-an update. Clin Infect Dis 2004; 39: Suppl. 3, S142-S150.
73. Zhanel GG, Hoban DJ. Ketolides in the treatment of respiratory infections. Expert Opin Pharmacother 2002; 3: 277-297.
74. Hansen LH, Mauvais P, Douthwaite S. The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Mol Microbiol 1999; 31: 623-631.
75. Agouridas C, Denis A, Auger JM, et al. Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and-susceptible respiratory pathogens. J Med Chem 1988; 41: 4080-4100.
76. Descheemaeker P, Chapelle S, Lammens C, et al. Macrolide resistance and erythromycin resistance determinants among BelgianStreptococcus pyogenesandStreptococcus pneumoniaeisolates. J Antimicrob Chemother. 2000; 45: 167-173.
77. Xiong L, Shah S, Mauvais P, et al. A ketolide resistance mutation in domain II of 23S rRNA reveals the proximity of hairpin 35 to the peptidyl transferase centre. Mol Microbiol 1999; 31: 633-639.
78. Yamaguchi T, Hirakata Y, Izumikawa K, et al. In vitroactivity of telithromycin (HMR3647), a new ketolide, against clinical isolates ofMycoplasma pneumoniaein Japan. Antimicrob Agents Chemother 2000; 44: 1381-1382.
79. US Food and Drug Federation. Ketek (telithromyin). www. fda. gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm152681. htm Date last accessed: October 2013. Date last updated: 2007.
80. Otsu K, Ishinaga H, Suzuki S, et al. Effects of a novel nonantibiotic macrolide, EM900, on cytokine and mucin gene expression in a human airway epithelial cell line. Pharmacology 2011; 88: 327-332.
81. Periti P, Mazzei T, Mini E, et al. Adverse effects of macrolide antibacterials. Drug Saf 1993; 9: 346-364.
82. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 2004; 10: S122-S129.
83. Malhotra-Kumar S, Lammens C, Coenen S, et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 2007; 369: 482-490.
84. Farrell DJ, Morrissey I, Bakker S, et al. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniaeandStreptococcus pyogenesisolated from the PROTEKT 1999-2000 study. J Antimicrob Chemother 2002; 50: Suppl. S1, 39-47.
85. Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J Infect 2004; 48: 56-65.
86. Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351: 1089-1096.
87. Svanström H, Pasternak B, Hviid A. Cardiovascular risks with azithromycin. N Engl J Med 2013; 369: 580-581.
88. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366: 1881-1890.
89. Jespersen CM, Als-Nielsen B, Damgaard M, et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ2006; 332: 22-27.
90. Schembri S, Williamson PA, Short PM, et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ2013; 346: f1235.
91. Albert RK, Connett J, Woodruff PG. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 367: 773-774.
92. Pessayre D, Larrey D, Funck-Brentano C, et al. Drug interactions and hepatitis produced by some macrolide antibiotics. J Antimicrob Chemother 1985; 16: Suppl. A, 181-194.
93. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Ther 1998; 64: 278-285.
94. Kantola T, Kivistö KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64: 177-182.
95. Von Rosensteil NA, Adam D. Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf 1995; 13: 105-122.